SecBot SecBot
SECBOTREPLAY Home › Report › ESPR

ESPR · The filing is a definitive merger proxy (DEFM14A) for Esperion…

Esperion Therapeutics, Inc. · DEFM14A filed Jun 8, 2026 at 06:02 ET

At the news

BULLISHIMPACT 7/10

DEFM14A filed Jun 8, 2026 at 06:02 ET

The filing is a definitive merger proxy (DEFM14A) for Esperion Therapeutics' acquisition by ArchiMed for $3.16/share plus one CVR per share. The board unanimously recommends a FOR vote. The deal requires majority approval of outstanding shares, with the special meeting on July 8, 2026. Total transaction costs are ~$1.08 billion, funded by $706.1M equity commitments and up to $550M debt. CVRs offer up to $100M in total contingent payments tied to sales milestones.

  • Merger consideration: $3.16/share cash + 1 CVR per share
  • Total funding ~$1.08B: $706.1M equity from ArchiMed funds + up to $550M debt commitment from BPCR/ BioPharma Credit
  • Special meeting July 8, 2026; required vote is majority of outstanding shares (257.7M shares outstanding)
  • CVRs: up to $40M aggregate if U.S. bempedoic acid net sales exceed $300M in CY 2027 (max $350M); up to $60M if enbumyst U.S. net sales exceed $160M in any single CY through 2030

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access